Bleeding

Vizient Task Force Releases Recommendations for Hospitals on Preparing for an Active Shooter Event

Retrieved on: 
Tuesday, April 2, 2024
Science, Public Policy, Government, Practice Management, Research, Medical Supplies, Health, Law Enforcement, Emergency Services, Hospitals, Organization, Communication, Disaster medicine, Risk, Patient, American Journal, Hospital, Trauma, Hope, Bleeding, Hospice and palliative medicine, Safety, Language, Risk management

Vizient, Inc. released recommendations focused on mitigating common risks, identifying national guidelines and utilizing existing resources to ensure preparedness for an active shooter event.

Key Points: 
  • Vizient, Inc. released recommendations focused on mitigating common risks, identifying national guidelines and utilizing existing resources to ensure preparedness for an active shooter event.
  • The recommendations were made by a task force of 40 Vizient network executives from 27 organizations across the country.
  • The recommendations and rationales bring attention to organizational tactics that were found by the task force to be lacking or inconsistent.
  • “It is an uncomfortable topic to discuss but it is vital that hospitals address the issue of a potential active shooter event,” said Susan Chishimba, Vizient Member Networks senior director.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Other Health, Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Interventional radiology, Thrombosis, TLR9, MDSC, Immunotherapy, Drug, Progression-free survival, Patient, Cancer, Bleeding, Society, University, Neoplasm, MD Anderson Cancer Center, Pancreas, FACS, Liver

Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting.

Key Points: 
  • Technology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting.
  • In PERIO-03, nelitolimod is delivered via the PEDD method with the TriSalus Infusion System using a retrograde venous approach, leveraging established interventional radiology access techniques.
  • There were no immediate complications from the procedure, and there was no evidence of hemorrhage or thrombosis.
  • Local tumor progression-free survival rates across organs at one month, six months, and one year were 94%, 80%, and 70%, respectively.

AI and automation have helped organizations respond to security incidents up to 99% faster than last year, according to new study from ReliaQuest

Retrieved on: 
Tuesday, March 26, 2024
Software, Networks, Internet, Artificial Intelligence, Data Management, Technology, Mobile, Wireless, Security, Automation, Web browser, Attention, Organization, PowerShell, MFA, Intelligence, Bleeding, Research, Limbo of the Lost, AI, Crime, MTTR, Denial-of-service attack, Email spoofing, Research report, Citrix Systems, Human

This is according to the ReliaQuest Annual Threat Report , which contains in-depth analysis of key security incidents and research from the past year, offering insights into the threats that organizations face.

Key Points: 
  • This is according to the ReliaQuest Annual Threat Report , which contains in-depth analysis of key security incidents and research from the past year, offering insights into the threats that organizations face.
  • Drive-by compromise has been traditionally defined as the automatic download of a malicious file from a compromised website without user interaction.
  • However, in most cases reviewed during the reporting period, user action was involved—facilitating initial access in nearly 30% of incidents.
  • However, while AI-powered automation is being leveraged by attackers, it has also delivered a step change in defensive capabilities among organizations.

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, DTRA, Conditional sentence, Inflammation, Viral, Marburg virus disease, Human, TLR7, Therapy, Lassa mammarenavirus, Lassa fever, Bleeding, Toll-like receptor 7, Vaccine

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.
  • The objective of the program is to evaluate the efficacy of PRTX007 in a series of animal models for Lassa fever and establish an effective treatment method of Lassa virus in humans.
  • “Primmune has demonstrated broad spectrum antiviral activity with PRTX007 and with related compounds from our discovery and development program,” said Charlie McDermott, President, Chief Executive Officer and Director of Primmune Therapeutics.
  • “PRTX007’s novel immunologic approach has the potential for combination use with direct acting anti-viral agents – enabling widely applicable utility in the treatment of Lassa fever and other hemorrhagic viruses.”

Grant & Eisenhofer Wins Jury Trial in Wrongful Death Suit Against The University of Chicago Medical Center

Retrieved on: 
Wednesday, March 13, 2024
Legal, Hospitals, Neurology, Baby, Maternity, Professional Services, Family, University, Consumer, Health, Education, Blood pressure, Depression, Birth injury, Grief, Cerebral palsy, UCMC, Labour, Bleeding, Abdominal pain, G&E, Death, Grant & Eisenhofer, Resuscitation, Estate, Injury, HIE, Pain, Medicine, Nursing, Delivery, Omotola Jalade Ekeinde, Birth control

Leading plaintiffs’ law firm Grant & Eisenhofer won a jury verdict of over $14 million against The University of Chicago Medical Center, in a wrongful death lawsuit filed on behalf of the estate of a boy who was born at UCMC with catastrophic brain damage.

Key Points: 
  • Leading plaintiffs’ law firm Grant & Eisenhofer won a jury verdict of over $14 million against The University of Chicago Medical Center, in a wrongful death lawsuit filed on behalf of the estate of a boy who was born at UCMC with catastrophic brain damage.
  • James Varga in Cook County Circuit Court (Illinois), a 12-person jury found UCMC liable for the death of four-and-a-half-year-old Oluwasemilore “Praise” Oyedapo.
  • Grant & Eisenhofer represented Praise’s mother, Omotola Oyedapo, who was 33-weeks pregnant when she was brought by ambulance to UCMC on July 9, 2016.
  • The case is captioned: Olusoji Oyedapo, as Independent Administrator of the Estate of Oluwasemilore Praise Oyedapo v. The University of Chicago Medical Center d/b/a UChicago Medicine, 20 L 13797.

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Retrieved on: 
Wednesday, March 13, 2024
Neurology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Fast track (FDA), Psoriasis, Cell, Disease, Risk, Patient, Megakaryocyte, Immunoglobulin G, ITP, B cell, Quality of life, Platelet, Autoantibody, Gastrointestinal tract, CD38, Bleeding, Safety, Dravet syndrome, Blood, Lennox–Gastaut syndrome, Fatigue, Fiscal, Food, Autoimmune disease, Pharmaceutical industry

Takeda ( TSE:4502/NYSE:TAK ) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).
  • An interim analysis of the ongoing Phase 2 study demonstrated positive safety and efficacy results.
  • Based on these positive results, and following consultation with global health authorities, Takeda plans to initiate a global Phase 3 trial of mezagitamab in ITP in fiscal year 2024.
  • Results from the Phase 2 trial have no impact on the full year consolidated reported forecast for the fiscal year ending March 31, 2024 (Fiscal Year 2023).

Saranas Reveals Groundbreaking SAFE-MCS Study Results at CRT 2024

Retrieved on: 
Monday, March 11, 2024
Surgery, Medical Devices, Health, Clinical Trials, Cardiology, CRT, Aortic stenosis, Physician, Risk, Early, Patient, Percutaneous coronary intervention, Henry Ford Health, MCS, PROTECT, Morristown Medical Center, Henry Ford, PCI, Bleeding, EVAR, Safety, Structural heart disease, TAVR, FDA

“This study is the first of its kind to specifically evaluate bleeding complications in patients undergoing protected PCI, with independently adjudicated results.

Key Points: 
  • “This study is the first of its kind to specifically evaluate bleeding complications in patients undergoing protected PCI, with independently adjudicated results.
  • The Saranas Early Bird Bleed Monitoring System is the first and only FDA-approved device for real-time monitoring of endovascular bleed complications.
  • “We would like to thank the excellent team of physicians and coordinators who contributed to the success of this study,” commented Mike MacKinnon, CEO and President of Saranas.
  • Saranas is dedicated to establishing a new benchmark for bleed detection during and after endovascular procedures, with the goal of improving patient outcomes and decreasing healthcare expenses overall.”

Medcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis Portfolio

Retrieved on: 
Wednesday, April 3, 2024
Textile, Powder, Paralysis, Trauma, Neurosurgery, Surgeon, Publication, Bleeding, Safety, Innovation system, Convertible, FDA, Economics, Pharmaceutical industry

The Company intends to use the proceeds from this Offering to accelerate the development of its lead surgical product, LifeGel™ Absorbable Hemostatic Gel.

Key Points: 
  • The Company intends to use the proceeds from this Offering to accelerate the development of its lead surgical product, LifeGel™ Absorbable Hemostatic Gel.
  • Current hemostatic agents swell and can cause neurological issues, including paralysis, when used in confined spaces routinely addressed in spinal surgery.
  • Medcura's Chief Executive Officer Jim Buck stated, "We remain highly encouraged by the continued momentum and pace of successes around our Life™ platform of innovative surgical hemostatic agents.
  • Our new and existing investor partners understand, and are aligned with, the Company's strategy to seismically transform the $2.8 billion worldwide biosurgery market for hemostatic agents.

FDA Grants HemoSonics Expanded Use of its Critical Bleeding Management System with Special 510(k) Clearance

Retrieved on: 
Wednesday, April 3, 2024
Patient, Trauma, Hospital, Acquisition, Coagulopathy, Cartridge, Operating, Hemostasis, American Red Cross, Bleeding, Intensive care medicine, FDA, Liver, Journal of Cardiothoracic Surgery, Food, Medical device

DURHAM, N.C., April 3, 2024 /PRNewswire/ -- HemoSonics, a medical device company focused on acute bleeding management, today announced it has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of arterial blood samples with its Quantra QStat® Cartridge. HemoSonics' QStat Cartridge used with the Quantra Hemostasis Analyzer first received 510(k) clearance from the U.S. FDA in 2022 for use in venous whole blood samples. Today's announcement enables hospitals to further standardize and operationalize viscoelastic testing with an arterial and venous indication for both HemoSonics' QStat Cartridge and the QPlus® Cartridge.

Key Points: 
  • HemoSonics' Quantra® Hemostasis Analyzer provides comprehensive blood analysis that details critical bleeding disorders and helps clinicians manage patients back into hemostasis.
  • DURHAM, N.C., April 3, 2024 /PRNewswire/ -- HemoSonics , a medical device company focused on acute bleeding management, today announced it has received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of arterial blood samples with its Quantra QStat® Cartridge.
  • HemoSonics' QStat Cartridge used with the Quantra Hemostasis Analyzer first received 510(k) clearance from the U.S. FDA in 2022 for use in venous whole blood samples.
  • "The Quantra System now has the broadest range of FDA-cleared clinical indications of any cartridge-based viscoelastic testing system.